Platinum based chemotherapy

Phase 2

Regeneron Pharmaceuticals, Inc. (REGN)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

REGNPhase 2$57.3B

Platinum based chemotherapy Phase 2 Est. Readout

Platinum based chemotherapy• Carcinoma, Non-Small-Cell Lung112

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

6 competitors in Carcinoma, Non-Small-Cell Lung

LLYIMC-1121B (ramucirumab)

Phase 2

CASIrecombinant human Angiostatin protein

Drug Information

Target Indication

Carcinoma, Non-Small-Cell Lung

Clinical Trial

NCT06623656

Last updated: 8/26/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

REGN

Regeneron Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

AlirocumabPhase 3

Homozygous Familial Hypercholesterolemia

StatinPhase 3

Hypercholesterolemia

Intravitreal Aflibercept Injection (IAI)Phase 3

Neovascular Age-Related Macular Degeneration

LibtayoPhase 3

Non-Small Cell Lung Cancer

REGN5715Phase 3

Allergic Conjunctivitis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts